The dopamine receptor agonist apomorphine stabilizes neurotoxic α-synuclein oligomers

被引:2
|
作者
Lima, Vanderlei de Araujo [1 ,2 ]
Esquinelato, Rodrigo [1 ]
Carmo-Goncalves, Phelippe [1 ,2 ]
do Nascimento, Lucas Alex [1 ]
Lee, Hudson [3 ]
Eliezer, David [3 ]
Romao, Luciana [4 ]
Follmer, Cristian [1 ,2 ]
机构
[1] Univ Fed Rio de Janeiro, Dept Phys Chem, BR-21941909 Rio De Janeiro, Brazil
[2] Univ Fed Rio de Janeiro, Inst Chem, Grad Program Chem, Rio De Janeiro, Brazil
[3] Cornell Univ, Weill Cornell Med Coll, Dept Biochem, New York, NY USA
[4] Univ Fed Rio de Janeiro, Inst Biomed Sci, Rio De Janeiro, Brazil
基金
美国国家卫生研究院;
关键词
apomorphine; dopamine; neurotoxicity; oligomer; Parkinson's disease; alpha-synuclein; PARKINSONS-DISEASE; AMYLOID-BETA; MOTOR RESPONSE; IN-VIVO; FIBRILS; AGGREGATION; MODEL; PHARMACOKINETICS; TRANSMISSION; DYSFUNCTION;
D O I
10.1002/1873-3468.14263
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The misfolding and aggregation of the protein alpha-synuclein (aSyn) into potentially neurotoxic oligomers is believed to play a pivotal role in the neuropathogenesis of Parkinson's disease (PD). Herein, we explore how apomorphine (Apo), a nonselective dopamine D1 and D2 receptor agonist utilized in the therapy for PD, affects the aggregation and toxicity of aSyn in vitro. Our data indicated that Apo inhibits aSyn fibrillation leading to the formation of large oligomeric species (Apo-aSyn-O), which exhibit remarkable toxicity in mesencephalic dopaminergic neurons in primary cultures. Interestingly, purified Apo-aSyn-O, even at very low concentrations, seems to be capable of converting unmodified aSyn monomer into neurotoxic species. Collectively, our findings warn for a possible dangerous effect of Apo on aSyn misfolding/aggregation pathway.
引用
收藏
页码:309 / 322
页数:14
相关论文
共 50 条
  • [21] GROWTH-HORMONE RESPONSE TO APOMORPHINE, A DOPAMINE RECEPTOR AGONIST, IN NORMAL AGING AND IN DEMENTIA OF THE ALZHEIMER TYPE
    LAL, S
    NAIR, NPV
    THAVUNDAYIL, JX
    TAWAR, V
    TESFAYE, Y
    DASTOOR, D
    GAUTHIER, S
    GUYDA, H
    NEUROBIOLOGY OF AGING, 1989, 10 (03) : 227 - 231
  • [22] Synergistic actions of the dopamine receptor agonist apomorphine and the 5-HT2 receptor agonist m-CPP on the ejaculatory response in rats.
    Yonezawa, Akihiko
    Yoshizumi, Masaru
    Ebiko, Manabu
    Ise, shin-nosuke
    Kimura, Yukio
    Sakurada, Shinobu
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2007, 103 : 171P - 171P
  • [23] EFFECT OF "ENRICHED ENVIRONMENT" DURING DEVELOPMENT ON ADULT RAT BEHAVIOR AND RESPONSE TO THE DOPAMINE RECEPTOR AGONIST APOMORPHINE
    Hoffmann, L. C.
    Schuette, S. R. M.
    Koch, M.
    Schwabe, K.
    NEUROSCIENCE, 2009, 158 (04) : 1589 - 1598
  • [24] FAILURE OF APOMORPHINE TO INDUCE DOPAMINE RECEPTOR HYPERSENSITIVITY
    FLEMENBAUM, A
    PSYCHOPHARMACOLOGY, 1979, 62 (02) : 175 - 179
  • [25] Novel Alpha-Synuclein Oligomers Formed with the Aminochrome-Glutathione Conjugate Are Not Neurotoxic
    Sandro Huenchuguala
    Birgitta Sjödin
    Bengt Mannervik
    Juan Segura-Aguilar
    Neurotoxicity Research, 2019, 35 : 432 - 440
  • [26] Novel Alpha-Synuclein Oligomers Formed with the Aminochrome-Glutathione Conjugate Are Not Neurotoxic
    Huenchuguala, Sandro
    Sjodin, Birgitta
    Mannervik, Bengt
    Segura-Aguilar, Juan
    NEUROTOXICITY RESEARCH, 2019, 35 (02) : 432 - 440
  • [27] ANTICONFLICT EFFECTS OF LOW-DOSES OF THE DOPAMINE AGONIST APOMORPHINE IN THE RAT
    HJORTH, S
    ENGEL, JA
    CARLSSON, A
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1986, 24 (02) : 237 - 240
  • [28] The dopamine agonist apomorphine enhances conditioned pain modulation in healthy humans
    Treister, Roi
    Pud, Dorit
    Eisenberg, Elon
    NEUROSCIENCE LETTERS, 2013, 548 : 115 - 119
  • [29] GLUCOCORTICOID MODIFICATION OF SPINAL DOPAMINE RECEPTOR ACTIVATION BY APOMORPHINE
    HALL, ED
    TYLER, CV
    BRAIN RESEARCH, 1983, 267 (02) : 380 - 383
  • [30] BROMOCRIPTINE - DOPAMINE-RECEPTOR AGONIST
    DIPALMA, JR
    AMERICAN FAMILY PHYSICIAN, 1976, 14 (06) : 88 - 89